CliffBio
small molecule

AVERI

DESOGESTREL; ETHINYL ESTRADIOL

Loss of exclusivity—loss of exclusivity
CompanyAvion Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameAVERI
Active ingredientDESOGESTREL; ETHINYL ESTRADIOL
Strength0.15MG;0.03MG
Dosage formTABLET
RouteORAL-28
ModalitySmall molecule
FDA approvalMay 2025
Marketing statusRX

More from Avion Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

AVERI patent cliff — loss of exclusivity — | CliffBio